1369427-40-6 Usage
General Description
The chemical "(2R,3R)-3-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionic acid dicyclohexylamine salt" is a complex compound that consists of a dicyclohexylamine salt of the (2R,3R)-3-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionic acid. (2R,3R)-3-((S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl)-3-methoxy-2-methylpropionic acid dicyclohexylamine salt has a chiral center, indicated by the (2R,3R)- configuration, and includes a pyrrolidine ring structure. The tert-butoxycarbonyl (Boc) group is also present in the structure, which is commonly used as a protecting group in organic synthesis. The dicyclohexylamine salt form indicates that the compound is stabilized by the addition of dicyclohexylamine, a common base used in organic chemistry reactions. Overall, this compound is a complex molecule with multiple functional groups and is likely to have applications in organic synthesis and chemical research.
Check Digit Verification of cas no
The CAS Registry Mumber 1369427-40-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,6,9,4,2 and 7 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1369427-40:
(9*1)+(8*3)+(7*6)+(6*9)+(5*4)+(4*2)+(3*7)+(2*4)+(1*0)=186
186 % 10 = 6
So 1369427-40-6 is a valid CAS Registry Number.
1369427-40-6Relevant articles and documents
Process Development and GMP Production of a Conjugate Warhead: Auristatin F-HPA-Ala/TFA (XMT-1864/TFA)
Conlon, Patrick R.,Gurijala, Venu Reddy,Kaufman, Michael,Li, Dachang,Li, Jiuyuan,Li, Yuanyuan,Reddy, Bollu Satyanarayan,Wagler, Thomas,Wang, Zedong,Xu, Zhongmin,Yin, Mao,Yurkovetskiy, Aleksandr V.,Zhu, Lei
, (2022/03/01)
An efficient, large-scale manufacturing process is described for XMT-1864/TFA (1-TFA), an auristatin F derivative, used as a novel, highly potent, cytotoxic warhead in Mersana's oncology antibody-drug conjugate platforms. The process achieves high diastereomeric purity and controls the impurities with all intermediates readily isolated by crystallization or precipitation in high yield and purity. Protecting groups were selected to ensure tolerability, scalability, and stability of the intermediates under various solution-phase peptide coupling conditions. Crystallization of the final product was developed to remove specified impurities and provide a high-purity active warhead molecule for use in the bioconjugation processing. The convergent synthesis involving six non-GMP steps and five GMP steps has been carried out in multiple cGMP productions on 1-kg scale to produce 1-TFA in >98% chemical purity and 1% total diastereomeric contamination with ～50% overall yield for the GMP steps.
